| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
| Targets |
PLGA does not have a specific pharmacological target as it is a biodegradable polymer used for drug delivery. Its function is to serve as a carrier for the controlled release of therapeutic agents. The polymer degrades in vivo through hydrolysis of ester bonds, releasing the encapsulated drug over time. The degradation rate depends on factors such as molecular weight, lactide to glycolide ratio, and polymer chain end groups. PLGA is biocompatible and does not elicit significant immune responses, making it suitable for biomedical applications.
|
|---|---|
| ln Vitro |
In vitro, PLGA is used as a drug delivery vehicle for the controlled release of therapeutic agents. The polymer can be formulated into nanoparticles, microparticles, or implants for sustained drug release. The release rate is linked to the degradation rate of PLGA, which depends on molecular weight, lactide to glycolide ratio, and polymer chain end groups. PLGA is used in the formulation of non-aqueous drug delivery systems for sustained release of drugs. The polymer is biocompatible and does not affect cell viability at standard concentrations.
|
| ln Vivo |
In vivo, PLGA is used as a biodegradable carrier for the controlled release of drugs. The polymer degrades in the body through hydrolysis, releasing the encapsulated drug over time. The degradation products (lactic acid and glycolic acid) are metabolized and eliminated from the body. PLGA-based drug delivery systems can achieve sustained release in vivo. The polymer is used in various biomedical applications including drug delivery, tissue engineering, and medical devices. Its biocompatibility and biodegradability make it suitable for in vivo applications.
|
| Enzyme Assay |
In vitro experiments with PLGA typically involve the preparation of drug-loaded nanoparticles or microparticles. The polymer is dissolved in an organic solvent (e.g., dichloromethane or chloroform) along with the drug. The solution is then emulsified in an aqueous phase containing a surfactant. The organic solvent is evaporated, and the resulting particles are collected and dried. The drug release profile is measured by incubating the particles in buffer at 37°C and measuring the amount of drug released over time. The particle size, drug loading, and release kinetics can be characterized.
|
| Cell Assay |
In vitro cell-based assays using PLGA are performed to study the biocompatibility and drug delivery efficiency of PLGA-based formulations. Cells are incubated with PLGA nanoparticles or microparticles containing a drug or a fluorescent marker. Cellular uptake is assessed by fluorescence microscopy or flow cytometry. Cell viability is assessed using MTT or other cell viability assays. The release of the encapsulated drug and its effects on cells can be studied. The polymer is biocompatible and does not affect cell viability at standard concentrations.
|
| Animal Protocol |
In vivo animal experiments with PLGA are conducted to study the drug delivery and biodegradation of PLGA-based formulations. PLGA nanoparticles or implants containing a drug are administered to animals via various routes (e.g., subcutaneous, intramuscular, intravenous). The drug release profile is measured by collecting blood or tissue samples and measuring drug concentrations. The biodegradation of the polymer is assessed by histological examination of the implantation site. The polymer's biocompatibility and safety are evaluated by monitoring animal health and tissue responses.
|
| ADME/Pharmacokinetics |
PLGA (Resomer RG 502H) has a lactide to glycolide ratio of 50:50 and is acid-terminated. The polymer has a viscosity of 0.16-0.24 dL/g and a molecular weight of 7,000-17,000. For storage, the polymer is kept at room temperature in a dry place. PLGA is biodegradable and biocompatible. It is used in drug delivery and tissue engineering applications. The polymer's degradation rate depends on molecular weight, lactide to glycolide ratio, and polymer chain end groups. PLGA is intended for research use only.
|
| Toxicity/Toxicokinetics |
PLGA is considered to have low toxicity and is biocompatible. The degradation products (lactic acid and glycolic acid) are naturally occurring metabolites that are eliminated from the body. As a research chemical, it is intended for laboratory use only and is not for human consumption. Standard laboratory safety precautions should be followed when handling this compound, including the use of gloves and eye protection.
|
| References |
|
| Additional Infomation |
A polyester for use in absorbable sutures and surgical mesh, particularly suitable for ophthalmic surgery. A 2-hydroxypropionic acid polymer forms a 3,6-dimethyl-1,4-dioxanedione polymer with polymerized glycolic acid, which then forms a copolymer with a 1,4-dioxane-2,5-dione copolymer with a molecular weight of approximately 80,000 Daltons.
See also: Polylactic acid-glycolic acid copolymer 910 (note moved to). PLGA (Resomer RG 502H) (CAS 34346-01-5) is a biodegradable and biocompatible copolymer of poly(lactic acid) (PLA) and poly(glycolic acid) (PGA). It has a 50:50 lactide to glycolide ratio and is acid-terminated. PLGA has a viscosity of 0.16-0.24 dL/g and a molecular weight of 7,000-17,000. The polymer is used in drug delivery and tissue engineering applications. PLGA is low toxicity, biocompatible, and biodegradable, making it suitable for controlled release of active molecules in vivo. The compound is intended for research use only. |
| Molecular Formula |
(C3H6O3.C2H4O3)N
|
|---|---|
| Molecular Weight |
166.1293
|
| CAS # |
34346-01-5
|
| Related CAS # |
PLGA (75:25);34346-01-5
|
| PubChem CID |
36797
|
| Appearance |
White to off-white solid powder
|
| Density |
1.53 g/mL at 25 °C(lit.)
|
| Melting Point |
262 °C(lit.)
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
11
|
| Complexity |
99.2
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
0
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL
Ethanol :< 1 mg/mL H2O : < 0.1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (Infinity mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.0194 mL | 30.0969 mL | 60.1938 mL | |
| 5 mM | 1.2039 mL | 6.0194 mL | 12.0388 mL | |
| 10 mM | 0.6019 mL | 3.0097 mL | 6.0194 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
